Reduction of Blood Glucose Variability in Type 1 Diabetic Patients Treated By Pancreatic Islet Transplantation
- 1 December 2002
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (12), 2256-2262
- https://doi.org/10.2337/diacare.25.12.2256
Abstract
OBJECTIVE—To compare the glycemic profiles of patients with type 1 diabetes treated with either an implantable insulin pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS—The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal insulin infusion through an implantable pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were insulin independent, whereas three IAK patients had partial graft function and reduced exogenous insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events (P < 0.001) and 1.40 ± 0.42 and 1.32 ± 0.53 vs. 3.47 ± 1.66 mmol/l (P < 0.001), respectively. Furthermore, the mean glucose concentration and the glucose variability were comparable between SPK and IAK patients. Over 3 days, no hypoglycemic events were observed in SPK patients and insulin-independent IAK patients. A total of 4.12 ± 1.66 hypoglycemic events were detected in the IPII patient group, whereas only 0.66 ± 0.57 events were observed in IAK patients with partial graft function (P < 0.001). The duration of the hypoglycemic events was significantly longer in IPII patients as compared with IAK patients: 64 ± 33 vs. 30 ± 15 min for the day period and 130 ± 62 vs. 30 ± 27 min for the night period (P < 0.001). CONCLUSIONS—Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an implantable insulin pump requires insulin delivery by a closed loop.Keywords
This publication has 22 references indexed in Scilit:
- Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000)Diabetologia, 2001
- Continuous Subcutaneous Glucose Monitoring in Children With Type 1 DiabetesPEDIATRICS, 2001
- HUMAN ISLET TRANSPLANTATIONTransplantation, 2000
- Implantable insulin pumpsThe Lancet, 1999
- Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failureThe Lancet, 1999
- IMPROVED SURVIVAL IN PATIENTS WITH INSULIN-DEPENDENT DIABETES MELLITUS AND END-STAGE DIABETIC NEPHROPATHY 10 YEARS AFTER COMBINED PANCREAS AND KIDNEY TRANSPLANTATION1Transplantation, 1999
- Long Term Safety and Efficacy of Intraperitoneal Insulin Infusion by Means of Implantable PumpsHormone and Metabolic Research, 1998
- Islet transplantation in IDDM patientsDiabetologia, 1997
- Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison With Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue During Ordinary Life ConditionsDiabetes Care, 1997
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993